Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...
XMRV was originally described in 2006 in the tumour tissue of patients with a familial form of prostate cancer associated with mutations that impair the function of the antiviral defence protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results